Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma
Surgical resection remains a first-line therapy for glioblastoma multiforme (GBM). Increased extent of resection (EOR) of noncontrast-enhancing regions in T2-weighted MRI images (T2-EOR) provides a survival benefit for GBM patients receiving standard radio/chemotherapy. However, whether it also impr...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.877190/full |
| _version_ | 1811251334359285760 |
|---|---|
| author | Xiaohan Chi Xiaohan Chi Yi Wang Yi Wang Chunzhao Li Chunzhao Li Xijian Huang Hua Gao Yang Zhang Yang Zhang Nan Ji Nan Ji |
| author_facet | Xiaohan Chi Xiaohan Chi Yi Wang Yi Wang Chunzhao Li Chunzhao Li Xijian Huang Hua Gao Yang Zhang Yang Zhang Nan Ji Nan Ji |
| author_sort | Xiaohan Chi |
| collection | DOAJ |
| description | Surgical resection remains a first-line therapy for glioblastoma multiforme (GBM). Increased extent of resection (EOR) of noncontrast-enhancing regions in T2-weighted MRI images (T2-EOR) provides a survival benefit for GBM patients receiving standard radio/chemotherapy. However, whether it also improves immunotherapeutic outcomes remains unclear. We calculated the T2-EOR by comparing the preoperative and postoperative MRI T2 hyperintensity outside the enhancing tumour and correlated the T2-EOR with immunological and clinical outcomes from our published early-phase trial of heat shock protein peptide complex-96 (HSPPC-96) vaccination in treating a cohort of 19 patients with newly diagnosed GBMs (NCT02122822). Patients with higher T2-EOR exhibited shorter progression-free survival (PFS) (HR 11.29, p=0.002) and overall survival (OS) (HR 6.5, p=0.003) times than patients with lower T2-EOR. T2-EOR was negatively correlated with the levels of tumour specific immune response (TSIR) post-vaccination (R=-0.725, p<0.001) and absolute TSIR increase from pre- to post-vaccination (R=-0.679, p=0.001). Multivariate Cox regression models revealed that higher T2-EOR represented an independent risk factor for PFS (HR 19.85, p=0.0068) and OS (HR 21.24, p=0.0185) in this patient cohort. Taken together, increased T2-EOR deteriorated immunotherapeutic outcomes by suppressing TSIR, suggesting the potential of T2-EOR as an early biomarker for predicting the immunotherapeutic efficacy of HSPPC-96 vaccination. |
| first_indexed | 2024-04-12T16:17:59Z |
| format | Article |
| id | doaj.art-3021affba50f4927b1c45fcc314373c4 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T16:17:59Z |
| publishDate | 2022-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-3021affba50f4927b1c45fcc314373c42022-12-22T03:25:39ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-05-011210.3389/fonc.2022.877190877190Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating GlioblastomaXiaohan Chi0Xiaohan Chi1Yi Wang2Yi Wang3Chunzhao Li4Chunzhao Li5Xijian Huang6Hua Gao7Yang Zhang8Yang Zhang9Nan Ji10Nan Ji11Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaCure & Sure Biotech Co., LTD, Shenzhen, ChinaCure & Sure Biotech Co., LTD, Shenzhen, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaDepartment of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, ChinaChina National Clinical Research Center for Neurological Diseases, Beijing, ChinaSurgical resection remains a first-line therapy for glioblastoma multiforme (GBM). Increased extent of resection (EOR) of noncontrast-enhancing regions in T2-weighted MRI images (T2-EOR) provides a survival benefit for GBM patients receiving standard radio/chemotherapy. However, whether it also improves immunotherapeutic outcomes remains unclear. We calculated the T2-EOR by comparing the preoperative and postoperative MRI T2 hyperintensity outside the enhancing tumour and correlated the T2-EOR with immunological and clinical outcomes from our published early-phase trial of heat shock protein peptide complex-96 (HSPPC-96) vaccination in treating a cohort of 19 patients with newly diagnosed GBMs (NCT02122822). Patients with higher T2-EOR exhibited shorter progression-free survival (PFS) (HR 11.29, p=0.002) and overall survival (OS) (HR 6.5, p=0.003) times than patients with lower T2-EOR. T2-EOR was negatively correlated with the levels of tumour specific immune response (TSIR) post-vaccination (R=-0.725, p<0.001) and absolute TSIR increase from pre- to post-vaccination (R=-0.679, p=0.001). Multivariate Cox regression models revealed that higher T2-EOR represented an independent risk factor for PFS (HR 19.85, p=0.0068) and OS (HR 21.24, p=0.0185) in this patient cohort. Taken together, increased T2-EOR deteriorated immunotherapeutic outcomes by suppressing TSIR, suggesting the potential of T2-EOR as an early biomarker for predicting the immunotherapeutic efficacy of HSPPC-96 vaccination.https://www.frontiersin.org/articles/10.3389/fonc.2022.877190/fullglioblastomaextent of resectionimmunotherapeutic efficacycancer treatment vaccineHSPPC-96 |
| spellingShingle | Xiaohan Chi Xiaohan Chi Yi Wang Yi Wang Chunzhao Li Chunzhao Li Xijian Huang Hua Gao Yang Zhang Yang Zhang Nan Ji Nan Ji Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma Frontiers in Oncology glioblastoma extent of resection immunotherapeutic efficacy cancer treatment vaccine HSPPC-96 |
| title | Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma |
| title_full | Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma |
| title_fullStr | Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma |
| title_full_unstemmed | Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma |
| title_short | Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of HSPPC-96 Vaccination in Treating Glioblastoma |
| title_sort | resection of noncontrast enhancing regions deteriorated the immunotherapeutic efficacy of hsppc 96 vaccination in treating glioblastoma |
| topic | glioblastoma extent of resection immunotherapeutic efficacy cancer treatment vaccine HSPPC-96 |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.877190/full |
| work_keys_str_mv | AT xiaohanchi resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT xiaohanchi resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT yiwang resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT yiwang resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT chunzhaoli resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT chunzhaoli resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT xijianhuang resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT huagao resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT yangzhang resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT yangzhang resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT nanji resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma AT nanji resectionofnoncontrastenhancingregionsdeterioratedtheimmunotherapeuticefficacyofhsppc96vaccinationintreatingglioblastoma |